JP2022523301A - アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 - Google Patents

アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 Download PDF

Info

Publication number
JP2022523301A
JP2022523301A JP2021543226A JP2021543226A JP2022523301A JP 2022523301 A JP2022523301 A JP 2022523301A JP 2021543226 A JP2021543226 A JP 2021543226A JP 2021543226 A JP2021543226 A JP 2021543226A JP 2022523301 A JP2022523301 A JP 2022523301A
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
angptl7
acid molecule
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523301A5 (https=
Inventor
プラビーン、カビタ
シュールマン、クラウディア
グルスキ、ローレン
テスロヴィッチ ドスタル、ターニャ
アベカシス、ゴンサロ
バラス、アリス
コッポラ、ジョバンニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022523301A publication Critical patent/JP2022523301A/ja
Publication of JP2022523301A5 publication Critical patent/JP2022523301A5/ja
Priority to JP2024213170A priority Critical patent/JP2025023307A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021543226A 2019-01-23 2020-01-21 アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 Pending JP2022523301A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213170A JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962795665P 2019-01-23 2019-01-23
US62/795,665 2019-01-23
US201962880609P 2019-07-30 2019-07-30
US62/880,609 2019-07-30
US201962902683P 2019-09-19 2019-09-19
US62/902,683 2019-09-19
US201962909573P 2019-10-02 2019-10-02
US62/909,573 2019-10-02
PCT/US2020/014373 WO2020154268A2 (en) 2019-01-23 2020-01-21 Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213170A Division JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療

Publications (2)

Publication Number Publication Date
JP2022523301A true JP2022523301A (ja) 2022-04-22
JP2022523301A5 JP2022523301A5 (https=) 2023-01-30

Family

ID=69591771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543226A Pending JP2022523301A (ja) 2019-01-23 2020-01-21 アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療
JP2024213170A Pending JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213170A Pending JP2025023307A (ja) 2019-01-23 2024-12-06 アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療

Country Status (11)

Country Link
US (2) US11767526B2 (https=)
EP (1) EP3914711A2 (https=)
JP (2) JP2022523301A (https=)
KR (1) KR20210132045A (https=)
CN (1) CN113646432A (https=)
AU (1) AU2020210630C1 (https=)
CA (1) CA3126476A1 (https=)
IL (1) IL284700B2 (https=)
MX (1) MX2021008797A (https=)
SG (1) SG11202107497XA (https=)
WO (1) WO2020154268A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク． アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置
US20230357774A1 (en) * 2020-09-29 2023-11-09 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
WO2022115383A1 (en) * 2020-11-24 2022-06-02 Empirico Inc. Treatment of sos2 related diseases and disorders
US11865134B2 (en) 2021-02-26 2024-01-09 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
KR20240099232A9 (ko) * 2021-09-30 2025-12-10 리제너론 파마슈티칼스 인코포레이티드 Rho 구아닌 뉴클레오타이드 교환 인자 12[Rho Guanine Nucleotide Exchange Factor 12, ARHGEF12] 억제제를 이용한 녹내장 치료
JP2024538646A (ja) * 2021-10-01 2024-10-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＡＮＧＰＴＬ７を標的化するためのｉＲＮＡ組成物および方法
EP4453210A1 (en) * 2021-12-22 2024-10-30 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044903A1 (en) * 2016-08-30 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
JP2018164440A (ja) * 2017-03-28 2018-10-25 ヤンマー株式会社 作業車両の自律走行システム
JP2018164442A (ja) * 2017-03-28 2018-10-25 国立大学法人 熊本大学 皮膚有棘細胞癌の判定、予防又は治療方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033977T2 (en) 2004-08-23 2018-02-28 Sylentis Sau Treatment of eye disorders with siRNAs characterized by increased intraocular pressure
WO2008004719A1 (en) 2006-07-05 2008-01-10 Orientbio Co., Ltd Method for diagnosing cancer by detecting the methylation of transitional zones
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EP2494351B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Colon and rectal tumor markers and methods of use thereof
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2397559A1 (en) 2010-06-17 2011-12-21 Max-Delbrück-Centrum Für Molekulare Medizin Stage-specific biomarkers for the diagnosis of acute kidney injury
US20120010230A1 (en) 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
US8785139B2 (en) 2011-05-18 2014-07-22 Baxter International Inc. Modification-dependent activity assays
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US20130310546A1 (en) 2012-05-16 2013-11-21 Bater Healthcare Sa Nucleophilic catalysts for oxime linkage and use of nmr analyses of the same
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
CA2884455A1 (en) 2012-09-21 2014-03-27 Integragen A new method for classification of liver samples and diagnosis of focal nodule dysplasia, hepatocellular adenoma, and hepatocellular carcinoma
US9206423B2 (en) * 2012-12-30 2015-12-08 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
WO2014167529A1 (en) 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
US10011837B2 (en) * 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2948871A1 (en) 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
MX387420B (es) 2015-11-24 2025-03-18 Commw Scient Ind Res Org Producción de virus en cultivos celulares.
EP3380616A4 (en) 2015-11-24 2019-11-06 Commonwealth Scientific and Industrial Research Organisation MANUFACTURE OF VIRUSES IN BIRDS
US20190177391A1 (en) 2016-03-31 2019-06-13 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
SG11201901306XA (en) * 2016-08-19 2019-03-28 Toolgen Inc Artificially engineered angiogenesis regulatory system
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
WO2018090006A1 (en) 2016-11-14 2018-05-17 Memorial Sloan-Kettering Cancer Center Methods for drug discovery using stem cell-derived schwann cells
WO2018174861A1 (en) 2017-03-21 2018-09-27 Mprobe Inc. Methods and compositions for detecting early stage breast cancer with rna-seq expression profiling
WO2018175630A1 (en) 2017-03-23 2018-09-27 The Regents Of The University Of California Stimulation of hair growth by senescent cells and senescence associated secretory phenotype
CA3065317A1 (en) 2017-05-31 2018-12-06 Commonwealth Scientific And Industrial Research Organisation Trait selection in avians
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN111867614A (zh) 2018-01-18 2020-10-30 艾达奈特公司 抗lilrb抗体及其用途
GB201806118D0 (en) 2018-04-13 2018-05-30 Univ Edinburgh Macrophage use
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
JP2022535717A (ja) 2019-05-24 2022-08-10 エンピリコ インク． アンジオポエチン様７（ａｎｇｐｔｌ７）関連疾患の処置
US20230357774A1 (en) 2020-09-29 2023-11-09 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044903A1 (en) * 2016-08-30 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
JP2018164440A (ja) * 2017-03-28 2018-10-25 ヤンマー株式会社 作業車両の自律走行システム
JP2018164442A (ja) * 2017-03-28 2018-10-25 国立大学法人 熊本大学 皮膚有棘細胞癌の判定、予防又は治療方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENES TO CELLS, vol. 16, JPN6023053508, 2011, pages 243 - 259, ISSN: 0005232510 *
IOVS, vol. 52, no. 14, JPN6023053507, 2011, pages 4622, ISSN: 0005232511 *

Also Published As

Publication number Publication date
WO2020154268A3 (en) 2020-09-24
IL284700B1 (en) 2025-06-01
WO2020154268A9 (en) 2021-09-16
IL284700B2 (en) 2025-10-01
WO2020154268A2 (en) 2020-07-30
MX2021008797A (es) 2022-01-31
CN113646432A (zh) 2021-11-12
US11512309B2 (en) 2022-11-29
AU2020210630A1 (en) 2021-08-05
KR20210132045A (ko) 2021-11-03
US11767526B2 (en) 2023-09-26
US20200231965A1 (en) 2020-07-23
CA3126476A1 (en) 2020-07-30
AU2020210630C1 (en) 2026-04-09
JP2025023307A (ja) 2025-02-14
IL284700A (en) 2021-08-31
US20210277391A1 (en) 2021-09-09
AU2020210630B2 (en) 2025-10-23
EP3914711A2 (en) 2021-12-01
SG11202107497XA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
US11512309B2 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CN116249787A (zh) 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症
US20250250631A1 (en) Kelch Domain Containing 7B (KLHDC7B) Variants And Uses Thereof
US20240102013A1 (en) Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors
US20220089664A1 (en) Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors
US11845989B2 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
RU2812912C2 (ru) Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7)
KR20230148819A (ko) 글루코코르티코이드 및 안지오포이에틴-유사 7 (angptl7) 억제제를 이용한 염증의 치료
US12577562B2 (en) Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors
CA3141632A1 (en) Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors
EP4416286A1 (en) Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
CN116997653A (zh) 用糖皮质激素和血管生成素样7(angptl7)抑制剂治疗炎症
US20230023182A1 (en) Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204